33 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
19 Apr 24
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
5:16pm
allow the Company additional time to regain such compliance. However, there can be no assurance that the Panel will grant the Company's request
424B5
NLSP
NLS Pharmaceutics Ltd
22 Mar 24
Prospectus supplement for primary offering
10:24am
of the letter, or until July 8, 2024, to evidence compliance.
There can be no assurance that we will meet the minimum shareholders’ equity requirement
6-K
EX-10.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
. However, there can be no assurance that we will be able to successfully resolve such noncompliance.
In addition, as of June 30, 2023, our shareholders … the opportunity to present a plan to regain compliance.
There can be no assurance that Nasdaq will accept our plan to regain compliance or that we
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
in clinical trials, conducting clinical trials and general and administrative expenses. There can be no assurance that funds will be available
6-K
EX-99.3
4yyx6sx7e894nm 3eh3
8 Dec 22
Report of Foreign Private Issuer
4:30pm
F-3
f8ypymgrx 233q7z
6 Dec 22
Shelf registration (foreign)
4:41pm
6-K
EX-99.1
9uts x7o6
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
8az 2xnov48d5ph65kif
6 Oct 22
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.2
m0247c vpsr3
3 Oct 22
Report of Foreign Private Issuer
8:51am
F-1
91bbvd9ad 30plh1
10 Jun 22
Registration statement (foreign)
4:43pm
6-K
EX-10.1
8v8l5tz9z4
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
424B5
yv23t ji2e73embddsi
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-1.1
vbeexrb
4 Mar 22
Report of Foreign Private Issuer
4:02pm
424B5
85w2tqw
4 Mar 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
62nqtle5fxdke9q
28 Sep 21
Unaudited Interim Condensed Financial Statements
4:02pm
6-K
EX-99.1
jkd5mz043qudyt
28 Sep 21
Standby Equity Distribution Agreement
8:30am
20-F
EX-4.6
hwwjj
14 May 21
Annual report (foreign)
5:05pm